Monoclonal Antibody, Human Interleukin 12/23 Inhibitors

The phrase "Monoclonal Antibody, Human Interleukin 12/23 Inhibitors" is a compendial and formulary classification title referring to targeted biologic agents that block both interleukin-12 (IL-12) and interleukin-23 (IL-23)

The phrase "Monoclonal Antibody, Human Interleukin 12/23 Inhibitors" is a compendial and formulary classification title referring to targeted biologic agents that block both interleukin-12 (IL-12) and interleukin-23 (IL-23)

Rather than a broad multi-agent drug family, this category is practically represented by human monoclonal antibodies targeting the shared p40 protein subunit of IL-12 and IL-23, principally ustekinumab and its biosimilars By preventing these cytokines from binding to their cell-surface receptors, these agents interrupt downstream inflammatory signaling cascades mediated by T-helper 1 (Th1) and T-helper 17 (Th17) immune pathways Clinically, they are primarily indicated for the treatment of modera...

Clinically, they are primarily indicated for the treatment of moderate-to-severe immune-mediated inflammatory disorders, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis